iodine I 131 tositumomab + fludarabine

Iodine I 131 tositumomab + fludarabine is a combination regimen investigated for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Iodine I 131 tositumomab is a radioimmunotherapeutic agent consisting of a murine IgG1 monoclonal antibody (tositumomab) directed against the CD20 antigen, covalently linked to the radioisotope iodine-131. It delivers targeted beta and gamma radiation directly to CD20-expressing B-cells, inducing cell death through ionizing radiation and antibody-dependent mechanisms. In the specific research context at the Fred Hutchinson Cancer Center, this agent is combined with fludarabine, a purine analog chemotherapy that inhibits DNA synthesis. This combination is used as a myeloablative conditioning regimen prior to autologous or syngeneic stem cell transplantation, particularly in older patients (aged 60 years and older), based on preclinical evidence suggesting synergy between the targeted radiation and the chemotherapy agent.

Brand names

Bexxar

Other names

iodine I 131 tositumomab + fludarabine phosphateI131-tositumomab and fludarabine conditioningI-131-tositumomab and fludarabine conditioningI 131-tositumomab and fludarabine conditioning